Back

Risk of all-cause mortality and heart failure hospitalizations in patients treated with vericiguat in real world settings

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Amyloid and acute heart failure therapy advances Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Fabian Kerwagen

University Hospital Wuerzburg, Wuerzburg (Germany)

6 More presentations in this session

Presentation thumbnail
Pillars of heart failure therapy: improving LV function in conventional cardiac pacing
Assistant Professor L. Cirin (Timisoara, RO)
Abstract Slides Video
Presentation thumbnail
SGLT2 inhibitor use in underweight patients with diabetes mellitus and heart failure
Doctor Y. Fujimoto (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Pre- and post- discharge implementation of medical therapy in patients hospitalized due to acute heart failure: a multinational observational registry
Doctor M. Manzoni (Brescia, IT)
Abstract Slides Video
Presentation thumbnail
Impact of Tafamidis on clinical outcomes in real-world patients with ATTR-CM
Doctor I. Araujo (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Mineralocorticoid receptor antagonists in heart failure with mildly reduced and preserved ejection fraction: an updated systematic review and meta-analysis of randomized clinical trials
Doctor D. Rodolico (Pisa, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Amyloid and acute heart failure therapy advances

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Impact of worsening heart failure events and renal impairment on vericiguat drug use patterns in real-world care
thumbnail
Congress Presentation
Incidence of cardiovascular events following vericiguat initiation in patients with heart failure with or without a recent worsening heart failure event: a hospital-based real-world cohort study
thumbnail
Congress Presentation
Clinical characteristics and outcomes in a cohort of patients starting treatment with vericiguat in the US.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources